INS and diabetes mellitus: Although this policy ensures that patients have access to necessary diabetes management devices without direct costs, the actual uptake of insulin pump therapy remains limited despite the growing evidence supporting their positive impact on the overall quality of life, including improved glycaemic control and increased flexibility in daily diabetes management (30–32).